Stephen L Lessnick
Overview
Explore the profile of Stephen L Lessnick including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
5382
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bayanjargal A, Taslim C, Showpnil I, Selich-Anderson J, Crow J, Lessnick S, et al.
bioRxiv
. 2024 Feb;
PMID: 38352344
Ewing sarcoma is the second most common bone cancer in children and young adults. In 85% of patients, a translocation between chromosomes 11 and 22 results in a potent fusion...
2.
Dubois S, Krailo M, Glade-Bender J, Buxton A, Laack N, Randall R, et al.
J Clin Oncol
. 2023 Jan;
41(11):2098-2107.
PMID: 36669140
Purpose: Monoclonal antibodies directed against insulin-like growth factor-1 receptor (IGF-1R) have shown activity in patients with relapsed Ewing sarcoma. The primary objective of Children's Oncology Group trial AEWS1221 was to...
3.
Lu D, Ellegast J, Ross K, Malone C, Lin S, Mabe N, et al.
Nat Cell Biol
. 2023 Jan;
25(2):285-297.
PMID: 36658220
Transcription factors (TFs) are frequently mutated in cancer. Paediatric cancers exhibit few mutations genome-wide but frequently harbour sentinel mutations that affect TFs, which provides a context to precisely study the...
4.
Shulman D, Chen S, Hall D, Nag A, Thorner A, Lessnick S, et al.
Br J Cancer
. 2022 Oct;
127(12):2220-2226.
PMID: 36221002
Background: Ewing sarcoma (EWS) is an aggressive sarcoma with no validated molecular biomarkers. We aimed to determine the frequency of STAG2 protein loss by immunohistochemistry (IHC) and whether loss of...
5.
Showpnil I, Selich-Anderson J, Taslim C, Boone M, Crow J, Theisen E, et al.
Nucleic Acids Res
. 2022 Sep;
50(17):9814-9837.
PMID: 36124657
Ewing sarcoma is a prototypical fusion transcription factor-associated pediatric cancer that expresses EWS/FLI or a highly related FET/ETS chimera. EWS/FLI dysregulates transcription to induce and maintain sarcomagenesis, but the mechanisms...
6.
Shulman D, Whittle S, Surdez D, Bailey K, de Alava E, Yustein J, et al.
NPJ Precis Oncol
. 2022 Sep;
6(1):65.
PMID: 36115869
The advent of dose intensified interval compressed therapy has improved event-free survival for patients with localized Ewing sarcoma (EwS) to 78% at 5 years. However, nearly a quarter of patients...
7.
Tokarsky E, Crow J, Guenther L, Sherman J, Taslim C, Alexe G, et al.
Mol Cancer Res
. 2022 Mar;
20(7):1035-1046.
PMID: 35298000
Implications: These findings demonstrate that mitochondrial dysfunction modulates SP-2509 efficacy and suggest that new therapeutic strategies combining LSD1 with agents that prevent mitochondrial dysfunction may benefit patients with this aggressive...
8.
Weaver D, Pishas K, Williamson D, Scarborough J, Lessnick S, Dhawan A, et al.
PLoS Comput Biol
. 2021 Oct;
17(10):e1008755.
PMID: 34662337
MicroRNA (miRNA)-based therapies are an emerging class of targeted therapeutics with many potential applications. Ewing Sarcoma patients could benefit dramatically from personalized miRNA therapy due to inter-patient heterogeneity and a...
9.
Boone M, Taslim C, Crow J, Selich-Anderson J, Watson M, Heppner P, et al.
Mol Cancer Res
. 2021 Sep;
19(11):1795-1801.
PMID: 34465585
Ewing sarcoma is a pediatric bone cancer defined by a chromosomal translocation fusing one of the FET family members to an ETS transcription factor. There have been seven reported chromosomal...
10.
Boone M, Taslim C, Crow J, Selich-Anderson J, Byrum A, Showpnil I, et al.
Oncogene
. 2021 Jun;
40(29):4759-4769.
PMID: 34145397
Ewing sarcoma is an aggressive bone cancer of children and young adults defined by the presence of a chromosomal translocation: t(11;22)(q24;q12). The encoded protein, EWS/FLI, fuses the amino-terminal domain of...